Gianluca TrifirÃ²

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7730403/publications.pdf

Version: 2024-02-01

235 papers

8,065 citations

44069 48 h-index

74 g-index

76900

244 all docs 244 docs citations

times ranked

244

10420 citing authors

#	Article	IF	CITATIONS
1	Assessing intravitreal anti-VEGF drug safety using real-world data: methodological challenges in observational research. Expert Opinion on Drug Safety, 2022, 21, 205-214.	2.4	4
2	Drug-induced Urinary Retention: An Analysis of a National Spontaneous Adverse Drug Reaction Reporting Database. European Urology Focus, 2022, 8, 1424-1432.	3.1	4
3	From Inception to ConcePTION: Genesis of a Network to Support Better Monitoring and Communication of Medication Safety During Pregnancy and Breastfeeding. Clinical Pharmacology and Therapeutics, 2022, 111, 321-331.	4.7	30
4	Overview of the <scp>European postâ€authorisation study</scp> register postâ€authorization studies performed in Europe from September 2010 to December 2018. Pharmacoepidemiology and Drug Safety, 2022, 31, 689-705.	1.9	9
5	Assessment of intravitreal anti-VEGF drugs and dexamethasone for retinal diseases in real world setting: A multi-centre prospective study from Southern Italy. European Journal of Ophthalmology, 2022, , 112067212110734.	1.3	O
6	A New Era of Pharmacovigilance: Future Challenges and Opportunities. Frontiers in Drug Safety and Regulation, 2022, 2, .	1.8	14
7	Efficacy of Systemic Biologic Drugs in Pediatric Psoriasis: Evidence From Five Selected Randomized Clinical Trials. Frontiers in Pharmacology, 2022, 13, 847308.	3.5	5
8	COVID-19 Patient Management in Outpatient Setting: A Population-Based Study from Southern Italy. Journal of Clinical Medicine, 2022, 11, 51.	2.4	8
9	Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management. BioDrugs, 2022, 36, 443-458.	4.6	20
10	Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database. Drug Safety, 2022, 45, 891-908.	3.2	18
11	Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database. British Journal of Clinical Pharmacology, 2021, 87, 527-541.	2.4	5
12	Pointâ€ofâ€Care test screening versus Case finding for paediatric coeliac disease: A pragmatic study in primary care. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 337-339.	1.5	2
13	Direct healthcare costs of chronic kidney disease management in Italy: What costâ€savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesisâ€stimulating agents?. Pharmacoepidemiology and Drug Safety, 2021, 30, 65-77.	1.9	3
14	Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors. Dermatologic Therapy, 2021, 34, e14830.	1.7	18
15	Comparison of Direct Oral Anticoagulant Use for the Treatment of Non-Valvular Atrial Fibrillation in Pivotal Clinical Trials vs. the Real-World Setting: A Population-Based Study from Southern Italy. Pharmaceuticals, 2021, 14, 290.	3.8	1
16	Characteristics and Absolute Survival of Metastatic Colorectal Cancer Patients Treated With Biologics: A Real-World Data Analysis From Three European Countries. Frontiers in Oncology, 2021, 11, 630456.	2.8	7
17	Chronic polytherapy after myocardial infarction: the trade-off between hospital and community-based providers in determining adherence to medication. BMC Cardiovascular Disorders, 2021, 21, 180.	1.7	1
18	The value of the polypill in cardiovascular disease: an Italian multidisciplinary Delphi panel consensus. Journal of Cardiovascular Medicine, 2021, 22, 246-258.	1.5	2

#	Article	IF	Citations
19	Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. Rheumatology, 2021, 60, SI25-SI36.	1.9	13
20	Kidney Disease in Diabetic Patients: From Pathophysiology to Pharmacological Aspects with a Focus on Therapeutic Inertia. International Journal of Molecular Sciences, 2021, 22, 4824.	4.1	35
21	Association of Influenza Vaccination and Prognosis in Patients Testing Positive to SARS-CoV-2 Swab Test: A Large-Scale Italian Multi-Database Cohort Study. Vaccines, 2021, 9, 716.	4.4	12
22	Are Patients with Psoriasis and Psoriatic Arthritis Undertreated? A Population-Based Study from Southern Italy. Journal of Clinical Medicine, 2021, 10, 3431.	2.4	14
23	Global epidemiology of acromegaly: a systematic review and meta-analysis. European Journal of Endocrinology, 2021, 185, 251-263.	3.7	33
24	Anti-hypertensive drugs deprescribing: an updated systematic review of clinical trials. BMC Family Practice, 2021, 22, 208.	2.9	7
25	Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project. BioDrugs, 2021, 35, 749-764.	4.6	16
26	Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update. BioDrugs, 2021, 35, 673-692.	4.6	19
27	COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety. Drug Safety, 2021, 44, 1247-1269.	3.2	85
28	Multidimensional Design and Analysis of a Data Mart Related to Healthcare Treatments with Biologic Drugs. , $2021, \ldots$		0
29	In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study. BioDrugs, 2020, 34, 55-64.	4.6	2
30	Choosing Among Common Data Models for Realâ€World Data Analyses Fit for Making Decisions About the Effectiveness of Medical Products. Clinical Pharmacology and Therapeutics, 2020, 107, 827-833.	4.7	29
31	Healthcare Database Networks for Drug Regulatory Policies: International Workshop on the Canadian, US and Spanish Experience and Future Steps for Italy. Drug Safety, 2020, 43, 1-5.	3.2	10
32	Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors. Thrombosis and Haemostasis, 2020, 120, 216-228.	3.4	48
33	Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines. Drug Safety, 2020, 43, 691-698.	3.2	102
34	A case of lung injury resembling diffuse pulmonary hemorrhage after the first administration of alemtuzumab in a patient with multiple sclerosis. Role of the HRCT. Monaldi Archives for Chest Disease, 2020, 90, .	0.6	1
35	Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations. Expert Review of Vaccines, 2020, 19, 919-936.	4.4	72
36	Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients. Drug Safety, 2020, 43, 1297-1308.	3.2	48

#	Article	IF	Citations
37	Traceability of Pediatric Antibiotic Purchasing Pathways in Italy: A Nationwide Real-World Drug Utilization Analysis. Frontiers in Pharmacology, 2020, 11, 1232.	3.5	2
38	Diagnostic accuracy of faecal calprotectin in a symptom-based algorithm for early diagnosis of inflammatory bowel disease adjusting for differential verification bias using a Bayesian approach. Scandinavian Journal of Gastroenterology, 2020, 55, 1176-1184.	1.5	1
39	Survival of Hospitalized COVID-19 Patients in Northern Italy: A Population-Based Cohort Study by the ITA-COVID-19 Network. Clinical Epidemiology, 2020, Volume 12, 1337-1346.	3.0	42
40	Real World Use of Antidiabetic Drugs in the Years 2011–2017: A Population-Based Study from Southern Italy. International Journal of Environmental Research and Public Health, 2020, 17, 9514.	2.6	5
41	Gender differences in COPD management in a Sicilian general practice setting: a cohort study evaluating the impact of educational interventions. ERJ Open Research, 2020, 6, 00279-2020.	2.6	2
42	Challenges for Drug Repurposing in the COVID-19 Pandemic Era. Frontiers in Pharmacology, 2020, 11, 588654.	3.5	99
43	â€~Use of antipsychotics in children and adolescents: a picture from the ARITMO population-based European cohort study'. Epidemiology and Psychiatric Sciences, 2020, 29, e117.	3.9	21
44	Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. Current Medical Research and Opinion, 2020, 36, 1457-1463.	1.9	40
45	Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks. BioDrugs, 2020, 34, 415-422.	4.6	50
46	Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet Journal of Rare Diseases, 2020, 15, 141.	2.7	202
47	Association Between Intravitreal Aflibercept and Serious Non-ocular Haemorrhage Compared with Intravitreal Ranibizumab: A Multicentre Observational Cohort Study. Drug Safety, 2020, 43, 943-952.	3.2	3
48	The potential role of big data in the detection of adverse drug reactions. Expert Review of Clinical Pharmacology, 2020, 13, 201-204.	3.1	5
49	Different Strategies to Execute Multiâ€Database Studies for Medicines Surveillance in Realâ€World Setting: A Reflection on the European Model. Clinical Pharmacology and Therapeutics, 2020, 108, 228-235.	4.7	32
50	How Have Intravitreal Anti-VEGF and Dexamethasone Implant Been Used in Italy? A Multiregional, Population-Based Study in the Years 2010–2016. BioMed Research International, 2020, 2020, 1-9.	1.9	4
51	Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports. Frontiers in Pharmacology, 2020, 11, 315.	3.5	9
52	Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?. Drug Safety, 2020, 43, 507-509.	3.2	20
53	Real-world use of biological drugs in patients with psoriasis/psoriatic arthritis: a retrospective, population-based study of years 2010-2014 from Southern Italy. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 441-451.	0.8	5
54	Access of medicines to the market: three years' experience of Sicily's regional drug formulary. Gazzetta Medica Italiana Archivio Per Le Scienze Mediche, 2020, 179, .	0.1	1

#	Article	IF	CITATIONS
55	Challenges in Post-marketing Studies of Biological Drugs in the Era of Biosimilars: A Report of the International Society for Pharmacoepidemiology 2019 Mid-Year Meeting in Rome, Italy. BioDrugs, 2019, 33, 345-352.	4.6	6
56	The International Society for Pharmacoepidemiology's Comments on the Core Recommendations in the Summary of the Heads of Medicines Agencies (HMA) â€-EMA Joint Big Data Task Force. Pharmacoepidemiology and Drug Safety, 2019, 28, 1640-1641.	1.9	2
57	Analgesic drug use in elderly persons: A population-based study in Southern Italy. PLoS ONE, 2019, 14, e0222836.	2.5	13
58	In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study. BMC Nephrology, 2019, 20, 359.	1.8	12
59	Measuring the Effectiveness of Safety Warnings on the Risk of Stroke in Older Antipsychotic Users: A Nationwide Cohort Study in Two Large Electronic Medical Records Databases in the United Kingdom and Italy. Drug Safety, 2019, 42, 1471-1485.	3.2	9
60	Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study. Drug Safety, 2019, 42, 1437-1447.	3.2	19
61	Inflammatory Bowel Disease Onset During Secukinumab Treatment: Real Concern or Just an Expression of Dysregulated Immune Response?. Clinical Drug Investigation, 2019, 39, 799-803.	2.2	22
62	Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study. Expert Opinion on Drug Safety, 2019, 18, 497-509.	2.4	24
63	Antipsychotic utilization patterns among patients with schizophrenic disorder: a cross-national analysis in four countries. European Journal of Clinical Pharmacology, 2019, 75, 1005-1015.	1.9	12
64	Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas. BMC Endocrine Disorders, 2019, 19, 18.	2.2	4
65	Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. Journal of Clinical Oncology, 2019, 37, 1336-1351.	1.6	73
66	Real-world insights on the management of migraine patients: an Italian nationwide study. Current Medical Research and Opinion, 2019, 35, 1545-1554.	1.9	11
67	Gender Differences in Outpatient Pediatric Drug Utilization: A Cohort Study From Southern Italy. Frontiers in Pharmacology, 2019, 10, 11.	3.5	16
68	Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Advances, 2019, 3, 1197-1210.	5.2	76
69	Pharmacological therapy in a rare disease: challenges in the long-term management of granulomatosis with polyangiitis. Expert Opinion on Orphan Drugs, 2019, 7, 521-523.	0.8	3
70	Workshop on the Italian Pharmacovigilance System in the International Context: Critical Issues and Perspectives. Drug Safety, 2019, 42, 683-687.	3.2	2
71	Identifying Data Elements to Measure Frailty in a Dutch Nationwide Electronic Medical Record Database for Use in Postmarketing Safety Evaluation: An Exploratory Study. Drug Safety, 2019, 42, 713-719.	3.2	5
72	All-cause mortality and antipsychotic use among elderly persons with high baseline cardiovascular and cerebrovascular risk: a multi-center retrospective cohort study in Italy. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 179-188.	3.3	8

#	Article	IF	CITATIONS
73	The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?. Drug Safety, 2019, 42, 347-363.	3.2	65
74	Diagnostic Yield of 2 Strategies for Adult Celiac Disease Identification in Primary Care. Journal of Clinical Gastroenterology, 2019, 53, 15-22.	2.2	5
75	Can information on functional and cognitive status improve short-term mortality risk prediction among community-dwelling older people? A cohort study using a UK primary care database. Clinical Epidemiology, 2018, Volume 10, 31-39.	3.0	12
76	NSAIDs utilization for musculoskeletal indications in elderly patients with cerebro/cardiovascular disease. European Journal of Clinical Pharmacology, 2018, 74, 637-643.	1.9	12
77	Improvement in the management of chronic obstructive pulmonary disease following a clinical educational program: results from a prospective cohort study in the Sicilian general practice setting. Npj Primary Care Respiratory Medicine, 2018, 28, 10.	2.6	9
78	Antidepressants and the risk of arrhythmia in elderly affected by a previous cardiovascular disease: a real-life investigation from Italy. European Journal of Clinical Pharmacology, 2018, 74, 119-129.	1.9	6
79	Association of Antidementia Drugs and Mortality in Community-Dwelling Frail Older Patients With Dementia: The Role of Mortality Risk Assessment. Journal of the American Medical Directors Association, 2018, 19, 162-168.	2.5	18
80	From Big Data to Smart Data for Pharmacovigilance: The Role of Healthcare Databases and Other Emerging Sources. Drug Safety, 2018, 41, 143-149.	3.2	54
81	Comparing safety information of biosimilars with their originators: a crossâ€sectional analysis of European risk management plans. British Journal of Clinical Pharmacology, 2018, 84, 738-763.	2.4	3
82	Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence. Expert Opinion on Biological Therapy, 2018, 18, 309-315.	3.1	32
83	Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy. Clinical Drug Investigation, 2018, 38, 269-278.	2.2	2
84	Treatment of Medication-Related Osteonecrosis of the Jaw and its Impact on a Patient's Quality of Life: A Single-Center, 10-Year Experience from Southern Italy. Drug Safety, 2018, 41, 111-123.	3.2	23
85	Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource. Alzheimer's and Dementia, 2018, 14, 130-139.	0.8	44
86	Pharmacokinetics of new oral anticoagulants: implications for use in routine care. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1057-1069.	3.3	37
87	Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. Drug Safety, 2018, 41, 1013-1022.	3.2	38
88	Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database. Endocrine, 2018, 61, 533-541.	2.3	24
89	The economic burden of preventable adverse drug reactions: a systematic review of observational studies. Expert Opinion on Drug Safety, 2018, 17, 681-695.	2.4	125
90	Can Electronic Health Records Databases Complement Spontaneous Reporting System Databases? A Historical-Reconstruction of the Association of Rofecoxib and Acute Myocardial Infarction. Frontiers in Pharmacology, 2018, 9, 594.	3.5	20

#	Article	IF	CITATIONS
91	Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report. Frontiers in Pharmacology, 2018, 9, 608.	3.5	8
92	Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009–2014. Frontiers in Endocrinology, 2018, 9, 95.	3.5	17
93	Bleeding events attributable to concurrent use of warfarin and other medications in high-risk elderly: meta-analysis and Italian population-based investigation. European Journal of Clinical Pharmacology, 2018, 74, 1061-1070.	1.9	7
94	First GCC stakeholder meeting on approval process, interchangeability/substitution and safety of biosimilars 2017 – Report. GaBI Journal, 2018, 7, 158-163.	0.3	1
95	Using a multidimensional prognostic index (MPI) based on comprehensive geriatric assessment (CGA) to predict mortality in elderly undergoing transcatheter aortic valve implantation. International Journal of Cardiology, 2017, 236, 381-386.	1.7	45
96	Antibiotic-Induced Liver Injury in Paediatric Outpatients: A Case-Control Study in Primary Care Databases. Drug Safety, 2017, 40, 305-315.	3.2	29
97	Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations: a population-based study during the years 2009–2015. Endocrine, 2017, 58, 143-152.	2.3	19
98	Use of azithromycin and risk of ventricular arrhythmia. Cmaj, 2017, 189, E560-E568.	2.0	42
99	Overview of the Safety of Anti-VEGF Drugs: Analysis of the Italian Spontaneous Reporting System. Drug Safety, 2017, 40, 1131-1140.	3.2	24
100	Exposure to statins is associated to fracture risk reduction in elderly people with cardiovascular disease: evidence from the ⟨scp⟩AIFA⟨ scp⟩â€⟨scp⟩Iâ€GrADE⟨ scp⟩ observational project. Pharmacoepidemiology and Drug Safety, 2017, 26, 775-784.	1.9	15
101	Antibiotic Use in Children – A Cross-National Analysis of 6 Countries. Journal of Pediatrics, 2017, 182, 239-244.e1.	1.8	90
102	Calcium Channel Blockers in Secondary Cardiovascular Prevention and Risk of Acute Events: Real-World Evidence from Nested Case–Control Studies on Italian Hypertensive Elderly. Clinical Drug Investigation, 2017, 37, 1165-1174.	2.2	4
103	Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project. European Journal of Clinical Pharmacology, 2017, 73, 1499-1510.	1.9	13
104	Balancing the Need for Personalization of QT Correction and Generalization of Study Results: Going Beyond Thorough QT Studies. Clinical Drug Investigation, 2017, 37, 985-988.	2.2	2
105	Combining evidence from multiple electronic health care databases: performances of one-stage and two-stage meta-analysis in matched case-control studies. Pharmacoepidemiology and Drug Safety, 2017, 26, 1213-1219.	1.9	7
106	Data Extraction And Management In Networks Of Observational Health Care Databases For Scientific Research: A Comparison Among EU-ADR, OMOP, Mini-Sentinel And MATRICE Strategies. EGEMS (Washington, DC), 2017, 4, 2.	2.0	43
107	Biological substantiation of antipsychotic-associated pneumonia: Systematic literature review and computational analyses. PLoS ONE, 2017, 12, e0187034.	2.5	20
108	Policies for biosimilar uptake in Europe: An overview. PLoS ONE, 2017, 12, e0190147.	2.5	153

#	Article	IF	Citations
109	Biosimilars in Italy: what do real-world data reveal?. GaBI Journal, 2017, 6, 114-119.	0.3	2
110	Building stakeholder confidence in biosimilar medicines through evidence-based information sharing. GaBI Journal, 2017, 6, 181-182.	0.3	0
111	Warfarin Treatment and Allâ€Cause Mortality in Communityâ€Dwelling Older Adults with Atrial Fibrillation: A Retrospective Observational Study. Journal of the American Geriatrics Society, 2016, 64, 1416-1424.	2.6	35
112	Prescribing pattern of antipsychotic drugs during the years 1996–2010: a populationâ€based database study in Europe with a focus on torsadogenic drugs. British Journal of Clinical Pharmacology, 2016, 82, 487-497.	2.4	27
113	Absorbable phosphate in medication. Kidney International, 2016, 89, 721.	5.2	O
114	How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009–2014. BioDrugs, 2016, 30, 295-306.	4.6	30
115	Relation of Statin Use and Mortality in Community-Dwelling Frail Older Patients With Coronary Artery Disease. American Journal of Cardiology, 2016, 118, 1624-1630.	1.6	52
116	Anticholinergic Medication Burden and 5-Year Risk of Hospitalization and Death in Nursing Home Elderly Residents With Coronary Artery Disease. Journal of the American Medical Directors Association, 2016, 17, 1056-1059.	2.5	43
117	Adverse drug reactions associated with off-label use of ketorolac, with particular focus on elderly patients. An analysis of the Italian pharmacovigilance database and a population based study. Expert Opinion on Drug Safety, 2016, 15, 61-67.	2.4	11
118	The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study. CNS Drugs, 2016, 30, 1097-1109.	5.9	33
119	Antipsychotic use in dementia patients in a general practice setting: a Dutch population-based study. Epidemiology and Psychiatric Sciences, 2016, 25, 403-406.	3.9	2
120	Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study. Osteoporosis International, 2016, 27, 1857-1867.	3.1	33
121	Effects of a computerized decision support system in improving pharmacological management in high-risk cardiovascular patients: A cluster-randomized open-label controlled trial. Health Informatics Journal, 2016, 22, 232-247.	2.1	10
122	Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database. Journal of Clinical Pharmacy and Therapeutics, 2016, 41, 116-118.	1.5	18
123	The Management of Diabetes Mellitus in Patients with Chronic Kidney Disease: A Population-Based Study in Southern Italy. Clinical Drug Investigation, 2016, 36, 203-212.	2.2	12
124	Detecting adverse drug reactions following long-term exposure in longitudinal observational data: The exposure-adjusted self-controlled case series. Statistical Methods in Medical Research, 2016, 25, 2577-2592.	1.5	25
125	Use of oral contraceptives in three European countries: a population-based multi-database study. European Journal of Contraception and Reproductive Health Care, 2016, 21, 81-87.	1.5	12
126	Response to comment on: "antibiotic use varies substantially among adultsâ€"a crossâ€'national study from five European Countries in the ARITMO project― Infection, 2016, 44, 135-141.	4.7	1

#	Article	IF	CITATIONS
127	Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study. PLoS ONE, 2016, 11, e0155805.	2.5	27
128	The Role of Healthcare Databases in Pharmacovigilance of Psychotropic Drugs. , 2016, , 73-94.		0
129	The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort study. British Journal of Clinical Pharmacology, 2015, 80, 304-314.	2.4	25
130	Antipsychotic drug exposure and risk of pneumonia: a systematic review and meta-analysis of observational studies. Pharmacoepidemiology and Drug Safety, 2015, 24, 812-820.	1.9	49
131	Association of Individual Non-Steroidal Anti-Inflammatory Drugs and Chronic Kidney Disease: A Population-Based Case Control Study. PLoS ONE, 2015, 10, e0122899.	2.5	62
132	The advent of biosimilars for the treatment of diabetes: current status and future directions. Acta Diabetologica, 2015, 52, 423-431.	2.5	18
133	Trends in paediatric macrolide use in five European countries—a population-based study. European Journal of Clinical Pharmacology, 2015, 71, 991-999.	1.9	9
134	Indications of newer and older antiâ€epileptic drug use: findings from a southern Italian general practice setting from 2005–2011. British Journal of Clinical Pharmacology, 2015, 79, 1010-1019.	2.4	34
135	Erythropoiesis-Stimulating Agents: Dose and Mortality Risk., 2015, 25, 164-168.		14
136	Antipsychotic use in elderly patients and the risk of pneumonia. Expert Opinion on Drug Safety, 2015, 14, 1-6.	2.4	42
137	Drug Interactions with Levothyroxine Therapy in Patients with Hypothyroidism: Observational Study in General Practice. Clinical Drug Investigation, 2015, 35, 187-195.	2.2	28
138	Using real-world healthcare data for pharmacovigilance signal detection – the experience of the EU-ADR project. Expert Review of Clinical Pharmacology, 2015, 8, 95-102.	3.1	31
139	Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 883-892.	3.3	59
140	Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy. Journal of Neural Transmission, 2015, 122, 799-808.	2.8	7
141	How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009–2013. BioDrugs, 2015, 29, 275-284.	4.6	46
142	Development and Validation of a Score for Adjusting Health Care Costs in General Practice. Value in Health, 2015, 18, 884-895.	0.3	8
143	An overview of experimental and early investigational therapies for the treatment of polycystic kidney disease. Expert Opinion on Investigational Drugs, 2015, 24, 1199-1218.	4.1	12
144	Monoclonal antibodies for renal diseases: current concepts and ongoing treatments. Expert Opinion on Biological Therapy, 2015, 15, 1119-1143.	3.1	16

#	Article	IF	Citations
145	Trends in the prescription of antidiabetic medications from 2009 to 2012 in a general practice of Southern Italy: A population-based study. Diabetes Research and Clinical Practice, 2015, 108, 157-163.	2.8	39
146	Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study. Osteoporosis International, 2015, 26, 1499-1506.	3.1	23
147	Evaluating performance of electronic healthcare records and spontaneous reporting data in drug safety signal detection. International Journal of Clinical Pharmacy, 2015, 37, 94-104.	2.1	31
148	Antibiotic use varies substantially among adults: a cross-national study from five European Countries in the ARITMO project. Infection, 2015, 43, 453-472.	4.7	32
149	Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal Detection. Drug Safety, 2015, 38, 1201-1210.	3.2	49
150	Medication is an additional source of phosphate intake in chronic kidney disease patients. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 959-967.	2.6	13
151	How healthy is community-dwelling elderly population? Results from Southern Italy. Translational Medicine @ UniSa, 2015, 13, 59-64.	0.5	9
152	The Burden of Nephrotoxic Drug Prescriptions in Patients with Chronic Kidney Disease: A Retrospective Population-Based Study in Southern Italy. PLoS ONE, 2014, 9, e89072.	2.5	50
153	High Prevalence of Poor Quality Drug Prescribing in Older Individuals: A Nationwide Report From the Italian Medicines Agency (AIFA). Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2014, 69, 430-437.	3.6	86
154	Expert opinion of nephrologists about the effectiveness of low-protein diet in different stages of chronic kidney disease (CKD). International Journal of Food Sciences and Nutrition, 2014, 65, 1027-1032.	2.8	2
155	Safety Profile of Biological Medicines as Compared with Non-Biologicals: An Analysis of the Italian Spontaneous Reporting System Database. Drug Safety, 2014, 37, 961-970.	3.2	37
156	Acute Cerebellar Ataxia Following Meningococcal Group C Conjugate Vaccination. Journal of Child Neurology, 2014, 29, 128-130.	1.4	12
157	Chronic Kidney Disease Requiring Healthcare Services: A New Approach to Evaluate Epidemiology of Renal Disease. BioMed Research International, 2014, 2014, 1-6.	1.9	14
158	New therapeutic strategies under development to halt the progression of renal failure. Expert Opinion on Investigational Drugs, 2014, 23, 693-709.	4.1	18
159	Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?. Journal of Internal Medicine, 2014, 275, 551-561.	6.0	105
160	Pediatric drug safety surveillance in Italian pharmacovigilance network: an overview of adverse drug reactions in the years 2001 – 2012. Expert Opinion on Drug Safety, 2014, 13, 9-20.	2.4	36
161	Validation study in four health-care databases: upper gastrointestinal bleeding misclassification affects precision but not magnitude of drug-related upper gastrointestinal bleeding risk. Journal of Clinical Epidemiology, 2014, 67, 921-931.	5.0	49
162	Changes in the prescribing pattern of antidepressant drugs in elderly patients: an Italian, nationwide, population-based study. European Journal of Clinical Pharmacology, 2014, 70, 469-478.	1.9	31

#	Article	IF	Citations
163	Signal Detection of Potentially Drug-Induced Acute Liver Injury in Children Using a Multi-Country Healthcare Database Network. Drug Safety, 2014, 37, 99-108.	3.2	25
164	Parkinsonism and severe hypothyroidism in an elderly patient: a case of lithium toxicity due to pharmacological interactions. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 452-454.	1.5	7
165	Bridging Islands of Information to Establish an Integrated Knowledge Base of Drugs and Health Outcomes of Interest. Drug Safety, 2014, 37, 557-567.	3.2	49
166	Systemic antibiotic prescribing to paediatric outpatients in 5 European countries: a population-based cohort study. BMC Pediatrics, 2014, 14, 174.	1.7	86
167	Are the Safety Profiles of Antipsychotic Drugs Used in Dementia the Same? An Updated Review of Observational Studies. Drug Safety, 2014, 37, 501-520.	3.2	34
168	86 Comparison of Incidence Rates of Acute Pancreatitis and Pancreatic Cancer Among the General Population and Type 2 Diabetes Mellitus Patients Between Different Databases in the SAFEGUARD Project. Gastroenterology, 2014, 146, S-24.	1.3	0
169	Two-dimensional correlation analysis and multivariate time series analysis as innovative tools for the study and the comparison of the hydrocarbon distributions in marine antarctic cores. Marine Chemistry, 2014, 159, 9-18.	2.3	13
170	Pattern of Statin Use in Southern Italian Primary Care: Can Prescription Databases Be Used for Monitoring Long-Term Adherence to the Treatment?. PLoS ONE, 2014, 9, e102146.	2.5	38
171	A nationwide prospective study on prescribing pattern of antidepressant drugs in Italian primary care. European Journal of Clinical Pharmacology, 2013, 69, 227-236.	1.9	28
172	Idiopathic Acute Liver Injury in Paediatric Outpatients: Incidence and Signal Detection in Two European Countries. Drug Safety, 2013, 36, 1007-1016.	3.2	18
173	Postmarketing Safety Surveillance. Drug Safety, 2013, 36, 183-197.	3.2	91
174	Cycloâ€oxygenaseâ€2 inhibitors or nonselective <scp>NSAID</scp> s plus gastroprotective agents: what to prescribe in daily clinical practice?. Alimentary Pharmacology and Therapeutics, 2013, 38, 178-189.	3.7	13
175	A Reference Standard for Evaluation of Methods for Drug Safety Signal Detection Using Electronic Healthcare Record Databases. Drug Safety, 2013, 36, 13-23.	3.2	71
176	Effects of L'Aquila earthquake on the prescribing pattern of antidepressant and antipsychotic drugs. International Journal of Clinical Pharmacy, 2013, 35, 1053-1062.	2.1	14
177	Overuse of Prescription and OTC Non-Steroidal Anti-Inflammatory Drugs in Patients with Rheumatoid Arthritis and Osteoarthritis. International Journal of Immunopathology and Pharmacology, 2013, 26, 279-281.	2.1	21
178	Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project. Journal of the American Medical Informatics Association: JAMIA, 2013, 20, 184-192.	4.4	75
179	Design and validation of an automated method to detect known adverse drug reactions in MEDLINE: a contribution from the EU–ADR project. Journal of the American Medical Informatics Association: JAMIA, 2013, 20, 446-452.	4.4	54
180	Identification of acute myocardial infarction from electronic healthcare records using different disease coding systems: a validation study in three European countries. BMJ Open, 2013, 3, e002862.	1.9	101

#	Article	IF	CITATIONS
181	Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: a nationwide population-based study. Annals of the Rheumatic Diseases, 2013, 72, 694-700.	0.9	231
182	Burden of community-acquired pneumonia in Italian general practice: Table 1–. European Respiratory Journal, 2013, 42, 1739-1742.	6.7	28
183	Clinical and economic burden of adverse drug reactions. Journal of Pharmacology and Pharmacotherapeutics, 2013, 4, S73-S77.	0.4	329
184	Additional risk minimisation measures in the EU– are they eligible for assessment?. Pharmacoepidemiology and Drug Safety, 2013, 22, 1046-1053.	1.9	20
185	Prescribing pattern of glucose lowering drugs in the <scp>U</scp> nited <scp>K</scp> ingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone. British Journal of Clinical Pharmacology, 2013, 75, 861-868.	2.4	39
186	Drug-Induced Acute Myocardial Infarction: Identifying  Prime Suspects' from Electronic Healthcare Records-Based Surveillance System. PLoS ONE, 2013, 8, e72148.	2.5	41
187	Using Electronic Health Care Records for Drug Safety Signal Detection. Medical Care, 2012, 50, 890-897.	2.4	79
188	Academic output from EU-funded health research projects. Lancet, The, 2012, 380, 1903-1904.	13.7	4
189	The EU-ADR corpus: Annotated drugs, diseases, targets, and their relationships. Journal of Biomedical Informatics, 2012, 45, 879-884.	4.3	99
190	How Much are Biosimilars Used in Southern Italy?. BioDrugs, 2012, 26, 113-120.	4.6	14
191	Risk Minimization Activities of Centrally Authorized Products in the EU. Drug Safety, 2012, 35, 299-314.	3.2	31
192	Risk of Cardiac Valve Regurgitation with Dopamine Agonist use in Parkinson $\hat{E}\frac{1}{4}$ s Disease and Hyperprolactinaemia. Drug Safety, 2012, 35, 159-171.	3.2	42
193	The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease. Pharmacological Research, 2012, 65, 358-364.	7.1	53
194	Adverse Drug Reaction-Related Hospitalizations in Persons Aged 55 Years and Over. Drugs and Aging, 2012, 29, 225-232.	2.7	51
195	Clinically Significant Drug Interactions with Newer Antidepressants. CNS Drugs, 2012, 26, 39-67.	5.9	135
196	Electronic healthcare databases for active drug safety surveillance: is there enough leverage?. Pharmacoepidemiology and Drug Safety, 2012, 21, 611-621.	1.9	73
197	Adherence to gastroprotection during cyclooxygenase 2 inhibitor treatment and the risk of upper gastrointestinal tract events: A populationâ€based study. Arthritis and Rheumatism, 2012, 64, 2792-2802.	6.7	17
198	Suboptimal Gastroprotective Coverage of NSAID Use and the Risk of Upper Gastrointestinal Complications. Gastroenterology, 2011, 140, S-45.	1.3	0

#	Article	IF	CITATIONS
199	Adherence to Gastroprotective Agents and the Risk of Upper Gastrointestinal Complications in Coxib Users. Gastroenterology, 2011, 140, S-585.	1.3	1
200	Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems. Current Drug Metabolism, 2011, 12, 611-620.	1.2	119
201	Antipsychotic Drug Use and Community-Acquired Pneumonia. Current Infectious Disease Reports, 2011, 13, 262-268.	3.0	51
202	Combining electronic healthcare databases in Europe to allow for largeâ€scale drug safety monitoring: the EUâ€ADR Project. Pharmacoepidemiology and Drug Safety, 2011, 20, 1-11.	1.9	222
203	Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut, 2011, 60, 1650-1659.	12.1	54
204	EU-ADR healthcare database network vs. spontaneous reporting system database: preliminary comparison of signal detection. Studies in Health Technology and Informatics, 2011, 166, 25-30.	0.3	34
205	Risk of Ischemic Stroke Associated With Antidepressant Drug Use in Elderly Persons. Journal of Clinical Psychopharmacology, 2010, 30, 252-258.	1.4	51
206	Prescribing pattern of antipsychotic drugs in the Italian general population 2000–2005: a focus on elderly with dementia. International Clinical Psychopharmacology, 2010, 25, 22-28.	1.7	27
207	Prescribing pattern of antiâ€epileptic drugs in an Italian setting of elderly outpatients: a populationâ€based study during 2004–07. British Journal of Clinical Pharmacology, 2010, 70, 514-522.	2.4	41
208	Association of Community-Acquired Pneumonia With Antipsychotic Drug Use in Elderly Patients. Annals of Internal Medicine, 2010, 152, 418.	3.9	132
209	Cerebellar Stroke in Elderly Patient with Basilar Artery Agenesia: A Case Report. Journal of Stroke and Cerebrovascular Diseases, 2010, 19, 81-83.	1.6	2
210	Design and evaluation of a semantic approach for the homogeneous identification of events in eight patient databases: a contribution to the European EU-ADR project. Studies in Health Technology and Informatics, 2010, 160, 1085-9.	0.3	13
211	Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?. Pharmacoepidemiology and Drug Safety, 2009, 18, 1176-1184.	1.9	162
212	Newer and older antiepileptic drug use in Southern Italy: A population-based study during the years 2003–2005. Epilepsy Research, 2009, 85, 107-113.	1.6	35
213	Use of antipsychotics in elderly patients with dementia: Do atypical and conventional agents have a similar safety profile?. Pharmacological Research, 2009, 59, 1-12.	7.1	93
214	Drug Safety Information Through the Internet. Drug Safety, 2009, 32, 245-253.	3.2	11
215	The EU-ADR project: preliminary results and perspective. Studies in Health Technology and Informatics, 2009, 148, 43-9.	0.3	37
216	A semantic approach for the homogeneous identification of events in eight patient databases: a contribution to the European eu-ADR project. Studies in Health Technology and Informatics, 2009, 150, 190-4.	0.3	16

#	Article	IF	CITATIONS
217	Lipid-lowering drug use in Italian primary care: effects of reimbursement criteria revision. European Journal of Clinical Pharmacology, 2008, 64, 619-625.	1.9	17
218	Prescribing pattern of drugs in the treatment of osteoarthritis in italian general practice: The effect of rofecoxib withdrawal. Arthritis and Rheumatism, 2008, 59, 568-574.	6.7	36
219	STATINS FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR EVENTS IN ELDERLY PATIENTS: A PICTURE FROM CLINICAL PRACTICE WITHOUT STRONG EVIDENCE FROM CLINICAL TRIALS. Journal of the American Geriatrics Society, 2008, 56, 175-177.	2.6	13
220	BURDEN OF CARDIOVASCULAR DISEASES IN ELDERLY WITH PARKINSON'S DISEASE WHO START A DOPAMINE AGONIST AGENT. Journal of the American Geriatrics Society, 2008, 56, 371-373.	2.6	5
221	Prevalence and antihyperglycemic prescribing trends for patients with type 2 diabetes in Italy: A 4-year retrospective study from national primary care data. Pharmacological Research, 2008, 57, 358-363.	7.1	29
222	Prescribing pattern of anti-Parkinson drugs in Southern Italy: Cross-sectional analysis in the years 2003–2005. Parkinsonism and Related Disorders, 2008, 14, 420-425.	2.2	28
223	Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. Journal of Psychopharmacology, 2008, 22, 39-46.	4.0	89
224	Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003–2004. Pharmacoepidemiology and Drug Safety, 2007, 16, 552-559.	1.9	59
225	All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. Pharmacoepidemiology and Drug Safety, 2007, 16, 538-544.	1.9	71
226	Prescribing patterns of antiepileptic drugs in Italy: a nationwide populationâ€based study in the years 2000–2005. European Journal of Neurology, 2007, 14, 1317-1321.	3.3	81
227	Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting. International Journal of Clinical Pharmacy, 2007, 30, 44-50.	1.4	21
228	Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources. British Journal of Clinical Pharmacology, 2006, 62, 582-590.	2.4	47
229	Drug-drug Interactions and Statin Therapy. Southern Medical Journal, 2006, 99, 1325-1326.	0.7	6
230	Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. Journal of Hypertension, 2005, 23, 2093-2100.	0.5	163
231	Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999?2002. European Journal of Clinical Pharmacology, 2005, 61, 47-53.	1.9	54
232	Statin–macrolide interaction risk: a population-based study throughout a general practice database. European Journal of Clinical Pharmacology, 2005, 61, 615-620.	1.9	32
233	Adverse drug events in emergency department population: a prospective Italian study. Pharmacoepidemiology and Drug Safety, 2005, 14, 333-340.	1.9	57
234	Oral anticoagulant therapy in Italy: prescribing prevalence and clinical reasons. Pharmacological Research, 2004, 50, 601-603.	7.1	12

#	Article	IF	CITATIONS
235	Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective Cohort Study. Frontiers in Pharmacology, 0, 13, .	3.5	0